-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
PLP-Snyder530
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/plp-snyder530.gif)
| Category | SARS-CoV |
| Description | PLP Snyder530 is a potent papain-like protease (PLpro) inhibitor with an IC50 value of 6.4 μM. PLP_Snyder530 induces conformational changes in SARS-COV-2 papain-like protease, inhibiting SARS-CoV-2 replication. PLP Snyder530 can be used for SARS-CoV-2 research. |
Product Information
| Molecular Weight | 372.46 |
| Molecular Formula | C24H24N2O2 |
| Purity | ≥98% (HPLC) |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| In Vitro | PLP Snyder530 induces conformational changes manly in BL2 region and increases the activity against PLpro. |
| Target | IC50: 6.4 μM (papain-like protease) |
